<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="1237"><NormalizedQuery>Hospital AND Clínic AND i AND Provincial AND de AND Barcelona</NormalizedQuery><SearchResults><Trial Id="367216"><Indications><Indication>Vascular fistula</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2012-11-01T00:00:00Z</DateStart><Identifiers><Identifier>HOSPITAL CLINIC INVESTIGATIONAL COMMITTEE REGISTRATION: 2013/8042 (HOSPITAL CLINIC, BARCELONA, SPAIN</Identifier><Identifier>ISRCTN15802482</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Usual lifestyle alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>exercise program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>82</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine whether a postoperative exercise program could really increase arteriovenous fistula (AVF) maturation at 1 month, and was to determine if exercises after AVF creation could or could not be recommended. The invsetigator hypothesized that a postoperative exercise program would increase arteriovenous fistula maturation after its surgical creation.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of vascular structure/function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Physical Examination</EndpointIndex><EndpointIndex>End stage renal disease - Clinical Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TitleDisplay>Effect of a postoperative exercise program on arteriovenous fistula maturation</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects Received/Scheduled for Other Therapies - Subjects received/scheduled for hemodialysis</PatientSegment><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate></PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Fontsere</Name></ContactNames></Trial><Trial Id="267627"><Indications><Indication>Acute liver failure</Indication><Indication>Chronic liver failure</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Stem cell therapy</Technology></Technologies><CompaniesCollaborator><Company>Clinica Universidad de Navarra</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-25T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2012-003900-11</Identifier><Identifier>Liveradvance</Identifier><Identifier>NCT02857010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mesenchymal stem cell therapy (liver failure), Hospital Clinic of Barcelona/Clinica Universidad de Navarra alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this double-blind, placebo randomized, controlled trial is to investigate the effects of allogenic bone marrow derived mesenchymal stem cells (MSCs) transplantation on liver and other organ functions and systemic inflammation in patients with acute-on-chronic liver failure (ACLF). Expected results: therapy with MSCs could have beneficial effects on the evolution of patients with ACLF (modulation of inflammatory response and improvement of liver and extra-hepatic organ function) what</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Liveradvance: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure</TitleDisplay><BiomarkerNames><BiomarkerName>Ammonia </BiomarkerName><BiomarkerName> Bile acids and salts </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Hepatic venous pressure gradient </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Javier Fernandez, MD PhD</Name><Name>Javier Fernandez, MD, PhD</Name><Name>PERE GINES, MD PhD</Name><Name>Pere Ginès, MD, PhD</Name></ContactNames></Trial><Trial Id="86451"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-09T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016578-34</Identifier><Identifier>NCT01571466</Identifier><Identifier>RISVAC03</Identifier><Identifier>RisVac 03</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention><Intervention>disulfiram alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>2015 [ 1690064 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled...doses [ 1730248 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled... The purpose of this phase &lt;b&gt;I&lt;/b&gt;, double-blind study was to evaluate the safety and efficacy of the HIV-1 vaccine, MVA HIV-B in chronic HIV-1 infected patients successfully</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response - Virological breakthrough</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RISVAC03: A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Bonaventur Clotet</Name><Name>Felipe Garcia</Name><Name>Josep Gatell</Name><Name>Juan Quiros</Name></ContactNames></Trial><Trial Id="176830"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-15T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EUDRACT: 2007-002367-27</Identifier><Identifier>NCT00679497</Identifier><Identifier>R02</Identifier><Identifier>RISVAC02</Identifier><Identifier>RisVac02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected... In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of peripheral blood mononuclear cells (PBMC)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RisVac02: A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - HIV Seronegative Subjects</PatientSegment><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Josep M Gatell, MD</Name></ContactNames></Trial><Trial Id="64569"><Indications><Indication>HIV infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-08-23T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>DCV-02/MANON07</Identifier><Identifier>NCT00402142</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous dendritic cell vaccine (HIV-1 infection), University of Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Confirmed HIV infection CD4&gt; 450 x 10(6)/l Baseline VL&gt; 10,000 c/ml before any HAART Part &lt;b&gt;I&lt;/b&gt;, patients off HAART at least during 6 months Part II, patients on HAART with PVL&amp;lt; 200 copies/ml at least during 6 months Written informed consent</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Dendritic Cell Vaccine in HIV-1 Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Felipe García, MD, PhD</Name></ContactNames></Trial><Trial Id="247707"><Indications><Indication>Crohns disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-001083-35</Identifier><Identifier>NCT02622763</Identifier><Identifier>TOLDEC-CD-INTRA</Identifier><Identifier>TolDecCDintra</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tolerogenic dendritic cell therapy (injectable, Crohns disease), Hospital Clinic of Barcelona/Fundacio Clinic alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective is to evaluate the safety and clinical response of intralesional injection of autologous peripheral blood differentiated adult dendritic cells expanded tolerogenic ( tolerogenic dendritic cell therapy ) in patients with refractory Crohn's disease treatment.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Remission - Crohn's disease activity index (CDAI) score &lt; 150</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability - Drug related adverse event</EndpointIndex><EndpointIndex>Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy - Crohn's disease endoscopic index of severity (CDEIS) score</EndpointIndex><EndpointIndex>Crohns disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Inflammatory Bowel Disease Questionnaire (IBDQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TolDecCDintra: Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Active Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Daniel Benitez, BS (Biology) PhD</Name><Name>Elena Ricart, MD PhD</Name><Name>Elena Ricart, MD, PhD</Name><Name>Sara Varea</Name><Name>Sara Varea, BS (Biology)</Name></ContactNames></Trial><Trial Id="73490"><ActionsPrimaryInterventionsPrimary><Action>5-HT 2 receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Company><Company>Fundacion Clinic per a la Recerca Biomédica</Company><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-12T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2009-016519-40</Identifier><Identifier>APSEP</Identifier><Identifier>NCT01259973</Identifier><Identifier>TRA-065</Identifier><Identifier>TRA-065</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>haloperidol alone</Intervention><Intervention>risperidone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>h and until +24 h (depending on each scale used). Subjects would be hospitalized for 3 complete days (separated between them by 1 wash-out week after each treatment) from 8.00 h to 8.00 h of the following day at phase &lt;b&gt;I&lt;/b&gt; unit of '&lt;b&gt;Hospital&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; Sant Pau &lt;b&gt;i&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; la Santa Creu', in &lt;b&gt;Barcelona&lt;/b&gt;, in order to monitor the results obtained after each treatment. During their hospitalization, subjects would be given food and drink every 2-h.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Hormone Levels - Assessment of prolactin levels</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Neuropsychological Function - Assessment of attention</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of adverse events(AEs)/side effects</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of extra pyramidal symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Barnes Akathisia Rating Scale (BARS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Simpson Angus Scale (SAS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Sleep</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of aggressive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of positive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of psychotic symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by BPRS (Brief Psychiatric Rating Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by SANS (Schedule for Assessment of Negative Symptoms)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of ocular function</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP2D6_HUMAN_Duplication</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(A)</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(G)</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of subjects by VAS scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>APSEP: Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - CYP2D6_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Cytochrome P450 3A5 </BiomarkerName><BiomarkerName> Prolactin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Amalia Lafuente Flo, Pharmacology professor</Name><Name>Analía Azaro, Clinical Pharmacologist</Name><Name>Eva Ferrando Martorell, Pre-doc</Name><Name>Gemma Trias Lafuente, Psychologist</Name><Name>Ignasi Carrió Gasset, Head of Nuclear Med Service</Name><Name>Miquel Bernardo Arroyo, Head of Psychiatry</Name><Name>Rosa M Antonijoan, Clinical Pharmacologist</Name><Name>Sergi Mas Herrero, Pos-doc assistant professor</Name></ContactNames></Trial><Trial Id="221060"><Indications><Indication>Schizophrenia</Indication></Indications><CompaniesCollaborator><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-09-13T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02341131</Identifier><Identifier>PI 11/01958</Identifier></Identifiers><InterventionsControlDisplay><Intervention>psychoeducation alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cognitive remediation therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to analyze the role of a neurotrophic factor (brain-derived neurotrophic factor [BDNF]) as a putative biological marker of the cognitive recovery in schizophrenia following a Cognitive Remediation Therapy (CRT). Additionally, the role as outcome predictors of BDNF serum levels and the val66met polymorphism and data from functional and structural neuroimaging would be studied.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia</EndpointIndex><EndpointIndex>Schizophrenia - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Schizophrenia - Protocol Specified Other Endpoints - Assessment of sociodemographic outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with Neurocognitive Impairment</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(A)</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(G)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Brain-derived neurotrophic factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rafael Penadés, Ph.D.</Name></ContactNames></Trial><Trial Id="295871"><Indications><Indication>Keratitis</Indication></Indications><CompaniesSponsor><Company>Banc De Sang I Teixits</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-04-07T00:00:00Z</DateEnd><DateStart>2017-02-24T00:00:00Z</DateStart><Identifiers><Identifier>2016-001841-23</Identifier><Identifier>I.2016.010</Identifier><Identifier>NCT03084861</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Air Optix Night and Day contact lens alone</Intervention><Intervention>Lubristil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cord Blood Eye Drops alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> This is a multicenter, randomized, open-label, two-arms phase &lt;b&gt;I&lt;/b&gt;/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal sensibility, corneal opacity, visual acuity</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures - Assessment of corneal opacity</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other ocular disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-17T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Antonio Sabala, MD</Name><Name>Daniela Ortiz, MD</Name><Name>Dinara Samarkanova, MD</Name><Name>Javier Puig Galy, MD PHD</Name><Name>Josep Torras, MD</Name><Name>Marta Calatayud, MD</Name><Name>Miriam Barbany, MD</Name><Name>Pablo Martí, MD</Name><Name>Ruth Coll Bonet, MD</Name><Name>Sergi Querol Giner, MD PHD</Name><Name>Teresa Torrent, MD</Name><Name>Zoraida Del Campo Carrasco, MD</Name></ContactNames></Trial><Trial Id="104381"><Indications><Indication>Obesity</Indication></Indications><CompaniesCollaborator><Company>Fundacio Clinic Per A La Recerca Biomedica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-09T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2006-000567-28</Identifier><Identifier>NCT00555074</Identifier><Identifier>TROTA-1</Identifier><Identifier>TROTA-1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sodium tungstate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>44</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade &lt;b&gt;I&lt;/b&gt; and II).</Teaser><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of body composition</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex><EndpointIndex>Obesity - Assessment of Dietary Intake - Assessment of caloric intake</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters - Assessment of basal metabolic rate</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments - Changes in hormonal parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TROTA-1: Sodium Tungstate in Obesity</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Vidal, MD</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>